Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
Holding RGEN?
Track your performance easily
RGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$113.50 - $211.13
Previous Close$139.51
Volume1.40M
Average Volume (3M)683.76K
Market Cap
$7.81B
Enterprise Value$7.75B
Total Cash (Recent Filing)$809.15M
Total Debt (Recent Filing)$742.85M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Feb 19, 2025EPS Estimate
$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding56,006,498
10 Day Avg. Volume562,343
30 Day Avg. Volume683,758
Standard Deviation0.12
R-Squared0.16
Alpha0.00467
Financial Highlights & Ratios
Price to Book (P/B)4.19
Price to Sales (P/S)12.97
Price to Cash Flow (P/CF)46.30
P/FCF Ratio51.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.86
Enterprise Value/Gross Profit27.20
Enterprise Value/Ebitda85.47
Forecast
1Y Price Target
$192.13Price Target Upside29.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Repligen News
PremiumCompany Announcements
Repligen’s Strong Q3 and Strategic Moves
PremiumCompany Announcements
Repligen Reports Strong Q3 2024 with Revenue Growth
PremiumPre-Earnings
Is RGEN a Buy, Before Earnings?
PremiumCompany Announcements
Repligen Issues Update on Restatement and Maintains Revenue GuidanceBulls Say, Bears Say
Bulls Say
Market Recovery And Strategic PositioningThe bioprocess market shows signs of recovery with book-to-bill ratios trending up and consumables orders increasing, signaling that de-stocking has run its course, which supports RGEN's above-market growth profile and strategic positioning.
Product Launch And Revenue GrowthRGEN has maintained a steady cadence of around 10 new product launches per year across its portfolio, with new products launched in recent years significantly contributing to revenue growth.
Revenue Guidance And Growth ProspectsRGEN reaffirmed its underlying 2024 revenue guidance and updated the range to $627-642M, with expectations of core base business growth inflection of +11% y/y in 2H24, highlighting a strong growth outlook.
Bears Say
Acquisition RisksExecution risk is highlighted as a potential issue with the acquisition.
China Market ChallengesChina continues to be weak and will likely take some time to recover as government policy and local competition will slow the recovery.
Valuation ConcernsValuation remains a primary drawback, though current multiples are in line with historical averages.
---
Ownership Overview
0.65% Insiders
39.26% Mutual Funds
9.76% Other Institutional Investors
29.54% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $113.50 and its highest was $211.13 in the past 12 months.
What is Repligen Corp’s market cap?
Currently, no data Available
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Feb 19, 2025 which is in 98 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Nov 12, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.095.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is $0.46.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,006,496 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.43 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went up 16.37%.
Which hedge fund is a major shareholder of Repligen Corp?
Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 179M.
---
Repligen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$192.13 (29.30% Upside)
$192.13 (29.30% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 86.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.45%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
12.28%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q2 2024
0:00 / 0:00
---
RGEN Revenue Breakdown
99.94% Product revenue
0.06% Royalty and other income
---
RGEN Stock 12 Month Forecast
Average Price Target
$192.13
▲(29.30% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+22.87%
reiterated a buy rating 3 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +22.87% per trade.
---